Natera Inc Stock Price, News & Analysis

Natera, Inc. (NASDAQ: NTRA) has announced the launch and clinical validation of the Prospera Heart test for heart transplant assessment, marking a significant extension of its technology beyond kidney transplants. The test boasts an impressive AUC of 0.844, reducing cost and complexity in patient monitoring. Collaborations with the University of Utah and UC San Diego validated the test using over 350 biopsy-matched samples. Furthermore, the Prospera Heart test will play a key role in the NIH-funded DTRT study, which is fully enrolled with over 2,000 dd-cfDNA timepoints.

Natera, a leader in cell-free DNA testing, announced participation in several investor conferences. CEO Steve Chapman and CFO Mike Brophy will discuss Natera's growth in the genetic testing sector and its impact on healthcare. Upcoming events include:

• Canaccord Genuity 41st Annual Growth Conference: August 11, 2021, 5:30 a.m. PT
• Wells Fargo Healthcare Conference: September 10, 2021, 8:20 a.m. PT
• Morgan Stanley 19th Annual Global Healthcare Conference: September 13, 2021, 8:45 a.m. PT
• Baird Global Healthcare Conference: September 15, 2021, 12:45 p.m. PT

Webcasts available at investor.natera.com.

Natera, Inc. (NASDAQ: NTRA) reported Q2 2021 financial results showing total revenues of $142 million, a 64.2% increase from $86.5 million in Q2 2020. Product revenues surged by 70.7% to $137.2 million, driven by 375,700 tests processed, up 60.5%. The company raised its 2021 revenue guidance to $600-620 million. However, net loss widened to $116 million from $59.6 million year-over-year, with operating expenses rising 98.7% to $181.2 million.

Natera (NASDAQ: NTRA) announced the initiation of a phase III trial, the ZEST study, evaluating its Signatera test for identifying early-stage breast cancer patients for treatment with GSK's PARP inhibitor, niraparib. This trial aims to assess the efficacy and safety of niraparib in 800 patients post-surgery or after adjuvant therapy. The FDA has designated Signatera as a Breakthrough Device for multiple indications, enhancing its role in personalized medicine for oncology.

Natera, a leader in cell-free DNA testing, will announce its second quarter 2021 results on August 5, 2021, post-market close. A conference call is scheduled for 1:30 p.m. PT to discuss financial results, business activities, and future outlook. This will provide investors with insights into Natera's financial performance and strategic direction.

Natera (NASDAQ: NTRA) announced a new peer-reviewed study validating its Signatera molecular residual disease (MRD) assay for esophageal adenocarcinoma (EAC). The study involved 20 EAC patients and showed that Signatera had a sensitivity of 80% in detecting recurrence, with a median lead time of almost one year before clinical detection. MRD-positive patients had a disease-free survival of 14.2 months versus 51.2 months for MRD-negative patients. This research highlights the potential for Signatera to improve treatment decisions in the growing incidence of esophageal cancer.

Natera (NASDAQ: NTRA) has announced a new peer-reviewed study validating its Signatera molecular residual disease (MRD) assay for oligometastatic colorectal cancer (oligo mCRC). The study involved 112 patients and demonstrated that Signatera identified MRD positivity in 54% of cases post-surgery, with a sensitivity of 72%. Serial testing increased sensitivity to 91%, with 100% overall survival among those who remained MRD-negative. These findings aim to establish Signatera as a vital prognostic biomarker for guiding treatment decisions in this patient population.

Natera, a leader in cell-free DNA testing, announced the pricing of its public offering of 4,500,000 shares at $113.00 each, with expected closing on July 26, 2021. The offering includes a 30-day option for underwriters to buy an additional 675,000 shares. The offering is underpinned by a shelf registration statement filed with the SEC. Morgan Stanley, Goldman Sachs, Cowen, and SVB Leerink are managing the offering. Natera aims to enhance disease management globally, focusing on women's health, oncology, and organ health.

Natera, Inc. (Nasdaq: NTRA) has announced a proposed follow-on public offering to raise $350 million through the sale of its common stock. Additionally, underwriters may purchase up to $52.5 million more in shares. The offering is contingent on market conditions, and there are no guarantees regarding its completion or the terms. Major banks including Morgan Stanley and Goldman Sachs are managing the offering. This move is part of Natera's ongoing efforts to fund its operations and expand its impact in cell-free DNA testing.